healthcare
Australia's AMP Capital closes global infra fund at $3.4b
Australia’s AMP Capital has closed its latest global infrastructure fund with $3.4 billion in commitments. The target was $3 billion.
China-Australia biotech fund raises $31m
UniSA Ventures, a tech commercialization unit of the University of South Australia, has secured A$45 million ($31 million) from a group of Chinese investors for an Australia-focused biotechnology fund.
Norwest raises $2b for latest global VC fund
Norwest Venture Partners, a US-headquartered investor with a strong presence in India, has closed its latest global VC fund at $2 billion. It is the firm’s largest vehicle to date.
Permira closes seventh global PE fund at $12b
Permira has reached a final close on its seventh global private equity buyout fund at the hard cap of EUR11 billion ($12.1 billion).
Lok seeks $150m for fourth India fund
Indian venture capital firm Lok Capital is targeting $150 million for its fourth fund, which will invest in growth-stage companies with a potential for positive social impact.
LGT acquires India impact investor
LGT Group has acquired a majority stake in Indian impact investor Aspada from an investment arm of Open Society Foundations, a George Soros-founded charitable institute.
Japan's JPIC backs $33m round for Atonarp
Japan Post Investment Corporation (JPIC) has backed a $33 million Series C round for Atonarp, a Tokyo-based molecular diagnostics systems developer that uses artificial intelligence (AI).
China GPs: The Centurium strategy
After more than a decade with Warburg Pincus in China, David Li struck out on his own with Centurium Capital. Applying technology to traditional business models is central to his investment thesis
Malaysia's Kenanga launches late-stage VC fund
Malaysia’s Kenanga Investment Bank has launched a venture fund of undisclosed size that will invest exclusively in companies that have achieved unicorn status or are within 6-24 months of IPO.
Catalys seeks $100m for Japan healthcare VC fund
Newly established Japanese venture capital firm Catalys Pacific has launched its debut fund with a view to raise $100 million for investments in early-stage life science start-ups globally.
China's New Horizon Health raises $66m Series C
China-based New Horizon Health, which produces home cancer test kits, has raised $66 million in a Series C round of funding led by VMS Group, a Hong Kong-based investment firm.
China’s Allist Pharmaceuticals raises $171m Series A
Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
Endiya reaches $40m first close of second India VC fund
Endiya Partners, an early-stage VC investor based in India, has achieved a first close of $40 million for its second fund. The target is $70 million.
Qiming leads Series B for Chinese hospital chain operator
Qiming Venture Partners has led a Series B round of nearly RMB100 million ($14 million) for Shanghai-based private hospital chain operator SinoUnited Health.
PE investors commit $1b to JD.com's healthcare unit
A group including CITIC Private Equity, CICC Capital and Baring Private Equity Asia has agreed to invest $1 billion in the healthcare unit of Chinese e-commerce giant JD.com, acquiring a combined stake of 14.5%.
Chinese gene tech equipment maker raises $200m
MGI Tech, a Chinese manufacturer of equipment used in gene sequencing, has raised $200 million in funding led by Goldstone Investment, the PE arm under CITIC Securities, Green Pine Capital Partners and Orient Securities Capital Investment.
China-US biopharma player raises $47m Series C
Sirnaomics, a China and US-based biopharmaceutical company specializing in gene therapeutics, has raised $47 million in Series C funding across two tranches.
Tencent-backed O2O healthcare platform raises $250m
Trusted Doctors, a China-based online-to-offline (O2O) healthcare provider has raised a $250 million round led by Tencent Holdings, Gaw Capital Partners, and the VC arm of local property developer Country Garden.
IDG, CDH back China cancer testing kits producer
IDG Capital Partners and CDH Investments have led an RMB300 million ($45 million) Series B round for China-based Creative Biosciences, a manufacturer of testing kits for colon cancer.
Shiyu Capital closes second renminbi fund at $477m
Shiyu Capital, which focuses on growth-stage investments in Chinese healthcare companies, has closed its second renminbi-denominated fund at RMB3.2 billion ($477 million), beating the RMB3 billion target.
Chinese healthcare data management platform raises $74m
Miaojiankang, a China-based company that provides health data tracking, management, and analysis services through an online platform, has raised RMB500 million ($74 million) in a Series C round from China Pacific Insurance and Xiran Capital.
Tencent leads $74m round for China crowdfunding platform
Shuidi, the operator of Shuidichou, a Chinese crowdfunding platform for patients with critical medical conditions, has raised RMB500 million ($74 million) in a Series B round of funding led by existing investor Tencent Holdings.
Chinese gym operator SuperMonkey raises $53.5m
Chinese gym operator SuperMonkey has raised RMB360 million ($53.5 million) in a Series D round led by Starquest Capital and Yao Capital, a sport-focused PE firm co-founded by former NBA star Yao Ming.
CCV leads Series B for Chinese AI player Shukun
Shukun, a Chinese company that provides artificial intelligence (AI) technology used in the treatment of cardiovascular diseases, has raised RMB200 million ($29 million) in a Series B round led by China Creation Ventures.